ArticleTranslational vision science & technology2026
Ultra-Widefield OCTA Mapping of Epiretinal Macrophage-Like Cells in Patients With Retinal Vein Occlusion.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize the ultra-widefield distribution and morphology of epiretinal macrophage-like cells (eMLCs) in retinal vein occlusion (RVO) and assess their associations with retinal ischemia and macular edema. Methods: This cross-sectional study included 68 eyes with unilateral branch or central RVO and 68 unaffected fellow eyes as controls. All eyes underwent 24 × 20 mm ultra-widefield swept-source optical coherence tomography angiography (OCTA). The eMLC density and morphology were quantified using a machine-learning-based pipeline. Foveal avascular zone (FAZ) metrics, central subfield thickness (CST), and nonperfusion areas (NPAs) were analyzed. Exploratory duration-based subgroup analyses were also performed. Results: Compared with fellow eyes, RVO eyes showed higher eMLC density (3.69 [2.43] vs. 2.24 [1.12] cells/mm²), greater total eMLCs area (5.31 [3.83] vs. 2.87 [1.74] mm²), greater CST (411.50 [374.75] vs. 290.50 [35.00] µm), and larger FAZ area (0.360 [0.375] vs. 0.220 [0.165] mm²; all P < 0.001). Within-eye regional analyses showed lower eMLC density in the macular region than in the remaining retina (3.09 [1.57] vs. 4.06 [2.82] cells/mm²) and in NPAs than in the remaining retinal regions of the same image (2.39 [1.67] vs. 4.16 [1.89] cells/mm²; both P < 0.001). In RVO eyes, eMLC count was independently associated with disease duration, prior anti-VEGF injection number, and ischemic status. Conclusions: EMLCs are increased in RVO and show a spatially heterogeneous distribution pattern. In RVO eyes, eMLC count was associated with disease duration, prior anti-VEGF exposure, and ischemic status, whereas duration-based subgroup findings should be interpreted as exploratory. Translational Relevance: Ultra-widefield OCTA-based eMLCs quantification may provide a clinically accessible imaging biomarker for inflammatory involvement in RVO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.